Dominik Lautsch, PhD
Articles
April 13th 2021
Two Steps Forward, One Step Back: 50 Years of Societal Value From LDL-C–Lowering Therapies
Joanna P. MacEwan, PhD Lauren M. Zhao, BA Katie Everson, MS Larry Liu, MD, PhD Dominik Lautsch, PhD Fang Sun, MD, PhD Darius N. Lakdawalla, PhD
Low-density lipoprotein cholesterol (LDL-C)–lowering therapies have yielded significant value to society through reduced costs for both fatal and nonfatal cardiovascular disease events. The vast majority of this value has accrued to patients.
Latest Updated Articles
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
Published: September 26th 2024 | Updated: October 1st 2024
Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health
Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
Published: December 10th 2024 | Updated: January 23rd 2025
Fixed-Duration Acalabrutinib Plus Venetoclax Beats Chemoimmunotherapy in First-Line CLL; Adding Obinutuzumab Boosts PFS
